Professor Hu commonly known motto is “Six Syndromes Stem from the Eight Guiding Principles”. The most popular books are “Transmitting The Knowledge of Jing Fang”, “Understanding The teachings of Zhang Zhong Jing: The Six Syndromes of Classical Medicine”, “Classical Medicine System: Understanding the Six Syndrome and Shang Han Lun” and “In Memory of Professor Hu Xi-shu’s Dedication to Jing Fang”. Feng has published over 10 different books and multiple articles all advocating the understanding of the Jing Fang Medical System. Feng has been invited all over the world to teach the full classical system of the Six Syndromes of the Shang Han Za Bing Lun.īesides being involved in teaching, Dr. Feng’s energy has been devoted to the deepening the understanding of the classics. Feng is also a post doctorate tutor at the Beijing University of Chinese Medicine in the goal to advance the knowledge and understanding of Jing Fang Medical system. Feng graduated from the Beijing university of Chinese medicine, and taught at the Dong Zhi Men Hospital. Feng is also very active in promoting the Jing Fang Medical Approach to the world by first organizing and publishing all of the late Professor Hu Xi-shu’s clinical notes and experience and also by founding the Hu Xi-shu Research Association of Classical Medicine which regularly organizes educative webinars and online courses as well as yearly conferences bringing Jing Fang experts and practitioners together every year.ĭr. Feng is actively practice in clinic in various hospitals around Beijing including the Sino-Japanese Friendship Hospital Dr. Feng is also a visiting professor and a senior academic and medical advisor for many Chinese Medicine University and hospitals in China and abroad, such as the CM classics department for the Guangzhou University of TCM, the Wenzhou Integrated Chinese and Western Medicine Hospital and many more.ĭr. Feng Shi-lun, is professor, chief physician, and honorary President of the Beijing Traditional Chinese Medicine of Zhang Zhongjing Teachings Association. Depletion of hCINAP by RNA interference causes defects in Cajal body formation, histone transcription, and cell viability. hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Zhang J, Bai D, Ma X, Guan J, Zheng X (2014). Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Zhang J *, Wan L *, Dai X, Sun Y, Wei W (2014). Targeting Cdc20 as a novel cancer therapeutic strategy. Wang L *, Zhang J *, Wan L *, Zhou X, Wang Z, Wei W (2015). pVHL suppresses kinase activity of Akt in a proline-hydroxylation dependent manner. Guo J, Chakraborty AK, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang, L, Novak, J, Yuan, M, Cheng, JQ, Toker, A, Signroretti, S, Zhang, Q, Asara, JM, Kaelin, Jr, WG, Wei, W (2016). Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Zhang J *, Xu K *, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W (2016). TRAF2 and OTUD7B govern a ubiquitin-dependent switch regulating mTORC2 signaling complex. Wang B *, Jie Z *, Joo D, Ordureau A, Liu P, Gan W, Guo J, Zhang J, North BJ, Dai X, Cheng X, Bian X, Zhang L, Harper JW, Sun S # and Wei W # (2017). Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q #, Zhang J # (2017). Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Wan L *, Xu K *, Wei Y *, Zhang J *, Han T, Fry C, Zhang Z, Wan Y, Huang L, Yuan M, Xia W, Chang W, Huang W, Liu C, Chang Y, Liu J, Wu Y, Jin V, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W (2018). Developmental Cell, published online Dec. SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression. Zhang J *, Chen M *, Zhu Y *, Dai X, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin YM, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X #, Pandolfi PP #, Wei W # (2018). PD-L1 regulation and its role in cancer immunotherapy. Z hang J *, Dang F *, Ren J, Wei W (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3 SPOP to control cancer immune surveillance. Zhang J *, Bu X *, Wang H *, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ #, Sicinski P #, Wei W # (2018). Molecular mechanisms of targeted therapies and immun otherapies for cancerġ.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |